We can’t show the full text here under this license. Use the link below to read it at the source.
Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis
Effects of Glucagon-Like Peptide 1 Receptor Agonists on Rheumatoid Arthritis Patients
AI simplified
Abstract
GLP-1 receptor agonists led to significant reductions in RA disease activity and cardiovascular risk markers in 173 patients with rheumatoid arthritis.
- Patients treated with GLP-1 receptor agonists showed greater decreases in pain and body weight compared to the control group.
- Significant reductions in total cholesterol and glycosylated hemoglobin were observed in the treatment group.
- Within the GLP-1RA group, erythrocyte sedimentation rate, C-reactive protein, low-density lipoprotein cholesterol, and triglyceride levels also decreased significantly.
- Approximately one-third of patients in the treatment group stopped using the GLP-1RA, primarily due to gastrointestinal issues.
AI simplified
Key numbers
−0.03
Decrease in RA Disease Activity
Mean change score in RA disease activity for treatment vs. control groups
4.4 kg
Weight Loss
Average weight change in treatment group vs. control group (1.2 kg)
−10.3 mg/dL
Reduction in Total Cholesterol
Change in total cholesterol for treatment group vs. control group (+0.3 mg/dL)